Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey

References

• Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol. 2009;148:451–458.
   PubMed Web of Science ®Google Scholar
• Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1988;106:471–479.
   PubMed Web of Science ®Google Scholar
• Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–1694.
   PubMed Web of Science ®Google Scholar
• Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 2008;28:839–846.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev. 2012;88:937–941.
   PubMed Web of Science ®Google Scholar
• Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38:233–237.
   PubMedGoogle Scholar
• Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727–1730.
   PubMed Web of Science ®Google Scholar
• Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–1455.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–615.
   PubMed Web of Science ®Google Scholar
• Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after ıntravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology. 2015;122:1008–1015.
   PubMed Web of Science ®Google Scholar
• Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155:1119–1122.
   PubMed Web of Science ®Google Scholar
• Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol. 2014;92:577–581.
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–333.
   PubMed Web of Science ®Google Scholar
• Castellanos MA, Schwartz S, García-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2013;97:816–819.
   PubMed Web of Science ®Google Scholar
• Baumal CR, Goldberg RA, Fein JG. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2015;46:432–438.
   PubMed Web of Science ®Google Scholar
• Hoerster R, Muether P, Dahlke C, Mehler K, Oberthür A, Kirchhof B, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013;91:74–75.
   PubMed Web of Science ®Google Scholar
• Erol MK, Coban DT, Sari ES, Bilgin AB, Dogan B, Ozdemir O, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340–343.
   PubMed Web of Science ®Google Scholar
• Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015;35:667–674.
   PubMed Web of Science ®Google Scholar
• Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35:675–680.
   PubMed Web of Science ®Google Scholar
• Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol. 2013;155:150–158.
   PubMed Web of Science ®Google Scholar
• Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, et al; Early treatment for retinopathy of prematurity cooperative group. prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology. 2005;112:1564–1568.
   PubMed Web of Science ®Google Scholar
• Holmström G, Larsson E. Long-term follow-up of visual functions in prematurely born children–a prospective population-based study up to 10 years of age. J AAPOS. 2008;12:157–162.
   PubMed Web of Science ®Google Scholar
• Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al; BEAT-ROP Cooperative group. refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327–1333.
   PubMed Web of Science ®Google Scholar
• Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015;253:1677–1683.
   PubMed Web of Science ®Google Scholar
• Yi Z, Su Y, Zhou Y, Zheng H, Ye M, Xu Y, et al. Effects of ıntravitreal ranibizumab in the treatment of retinopathy of prematurity in chinese ınfants. Curr Eye Res. 2015:1–6. [Epub ahead of print] doi: 10.3109/02713683.2015.1084643.
   Google Scholar
• Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol. 2015;15:20. doi: 10.1186/s12886-015-0001-7.
   PubMed Web of Science ®Google Scholar
• Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. J AAPOS. 2014;18:120–123.
   PubMed Web of Science ®Google Scholar
• Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56:956–961.
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95–113.
   PubMed Web of Science ®Google Scholar
• Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000–1006.
   PubMed Web of Science ®Google Scholar
• Isaac M, Tehrani N, Mireskandari K; Medscape. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up. Eye (Lond). 2016 Feb 12. doi: 10.1038/eye.2015.289.
   Google Scholar
• Flynn JT, Chan-Ling T. Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol. 2006;142:46–59.
   PubMed Web of Science ®Google Scholar
• Kuo HK, Sun IT, Chung MY, Chen YH. Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotherapy. Ophthalmologica. 2015;234:211–217.
   PubMed Web of Science ®Google Scholar
• Smith EL 3rd. Prentice Award Lecture2010: A case for peripheral optical treatment strategies for myopia. Optom Vis Sci. 2011;88:1029–1044.
   PubMed Web of Science ®Google Scholar
• Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond). 2014;28:1080–1086.
   PubMed Web of Science ®Google Scholar
• Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol. 2014;98:507–512.
   PubMed Web of Science ®Google Scholar
• Hartnett ME. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol. 2014;41:925–943.
   PubMed Web of Science ®Google Scholar
• John VJ, McClintic JI, Hess DJ, Berrocal AM. Retinopathy of prematurity versus familial exudative vitreoretinopathy: report on clinical and angiographic findings. Ophthalmic Surg Lasers Imaging Retina. 2016;47:14–19.
   Google Scholar
• Padhi TR, Das T, Rath S, Pradhan L, Sutar S, Panda KG, et al. Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I. Eye (Lond). 2015;30:392–399.
   PubMed Web of Science ®Google Scholar
• Warden SM, Andreoli CM, S. Mukai The Wnt signaling pathway in familial exudative vitreoretinopathy and Norrie disease. Semin Ophthalmol. 2007;22:211–217.
   PubMedGoogle Scholar
• Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental outcomes in ınfants with retinopathy of prematurity and bevacizumab treatment. PLoS One. 2016;11(1):e0148019. doi: 10.1371/journal.pone.0148019
   PubMed Web of Science ®Google Scholar